Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Poteligeo

(poh-teh-LIH-gee-oh)
A drug used to treat adults with mycosis fungoides or Sezary syndrome (types of cutaneous T-cell lymphoma) that came back or did not get better after treatment with at least one systemic therapy. It is also being studied in the treatment of other types of cancer. Poteligeo binds to a protein called CCR4, which is found on some T cells (a type of white blood cell) and some types of lymphoma cells. Poteligeo may block this protein and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called mogamulizumab.
More Information
Search NCI's Dictionary of Cancer Terms